+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

ASH-EHA Translational Research Training in Hematology

American Society of Hematology

A joint effort of the American Society of Hematology (ASH) and the European Hematology Association (EHA), Translational Research Training in Hematology (TRTH) is a unique, year-long training and mentoring program focused on helping early stage researchers, including senior postdoctoral fellows and junior faculty, gain the tools necessary to build successful careers in blood-related translational research.

Each year, 24 early-career scientists (12 ASH Members and 12 EHA Members) are selected to participate in the prestigious and rigorous training program led by faculty who are international leaders in hematology. Topics covered include biostatistics and biomarkers, genetics and molecular biology, ethics, and phase I clinical study design.

AI Based Application Success Predictor

1. 🎯 Direct Relevance to Hematology

ASH funds projects in:

Blood cancers (leukemia, lymphoma, myeloma)

Non-malignant hematology (sickle cell disease, hemophilia, thrombosis, transfusion medicine)

Translational and clinical research to improve diagnostics, treatments, or patient outcomes

✅ Predictor: The project clearly advances hematologic science or patient care.

2. 👩‍🔬 Strong Support for Early-Career Investigators

ASH provides many programs for:

Medical students, residents, fellows, and junior faculty

Mentored career development grants to help transition to independence

✅ Predictor: Applicants with mentorship, training plans, and institutional support are more competitive.

3. 🧪 Feasibility and Preliminary Data

Successful proposals are well-defined, hypothesis-driven pilot projects

Projects with preliminary results or strong scientific rationale fare better

✅ Predictor: The research is achievable within the funding period and provides data for NIH/R01 grants.

4. 📚 Alignment with ASH’s Mission

ASH prioritizes research that:

Improves patient care and outcomes in hematology

Addresses health disparities or access to treatment

Trains the next generation of hematologists

✅ Predictor: The proposal clearly supports ASH’s goals in advancing hematology research and education.

5. 📈 Potential for Career Development and Future Funding

Many ASH awards emphasize:

Transition to independence (mentored → independent research)

Plans to secure NIH or equivalent funding

✅ Predictor: Applications include career goals, mentorship structure, and future grant plans.

🧾 ASH Grant & Fellowship Programs

Program	Amount	Audience	Purpose
ASH Scholar Awards	$100k–$150k/year (2–3 years)	Early-career faculty	Research career development
ASH Research Training Award for Fellows (RTAF)	$70k–$100k	Fellows	Transition to independent research
Medical Student and Resident Hematology Awards	$5k–$7k	Students/residents	Short-term hematology research
ASH Bridge Grants	$150k	Faculty	Interim funding for R01 resubmission

🧬 Commonly Funded Topics

Mechanisms and treatments of hematologic malignancies

Gene and cell therapies for blood disorders

Thrombosis and hemostasis research

Sickle cell disease, hemophilia, and rare blood disorders

Improving clinical trials and health equity in hematology care

📌 Tips for Strong Applications

✅ Provide clear, feasible aims with preliminary data if possible
✅ Include letters of support from mentors and institutions
✅ Show how results will lead to NIH or foundation funding
✅ Emphasize career development plans and training environment

Specialties

Hematology

Eligibility Requirements

Candidate Eligibility:

Applicants must be a trainee or junior faculty and hold an MD and/or PhD or biomedical PhD or pharmacy PharmD degree (or equivalents) in basic and translation research in classical or malignant hematology.
MD applicants must be within twelve years of post-graduation at the time of the deadline for full application. PhD applicants must have less than eight years of post-doc experience after graduation at the time of the deadline for full application. Applicants holding both an MD and a PhD must be within 12 years of MD-graduation. Exceptions may be made for interruptions in an applicant's academic pursuits. However, such circumstances must be explained by the applicant in the application. If you would like to request an exception, please, contact the ASH Training at training@hematology.org.
Applicants must be actively employed in a hematology or hematology-related research environment.
Proficiency in English is required.

Career stage:

At time of application and for the duration of the TRTH program, eligible applicants must be a junior faculty or in classical or malignant hematology-related fellowship training.
Fellowship training is defined as any sub-specialty training in hematology irrespective of whether this training is concurrent with another training program.

EHA and ASH membership:

Both the applicant and the applicant's mentor should be either an EHA member, or an ASH member at the time of LOI submission and throughout the term of the award program.

Institute and Mentor:

Applicants from the same institution are eligible to apply. However, no more than ONE participant working in the same lab/research unit will be selected and no more than TWO from the same institution.
Applicants with the same mentor are eligible to apply. However, no more than ONE participant from a specific mentor will be selected.
Institution is defined as the institution where the applicant will be conducting research during the TRTH Program year, NOT the location of a prior mentor or a department head at an institution the applicant may return to later.
Mentor is defined as the research supervisor at that institution.

Project eligibility:

The focus of the TRTH program is on laboratory-based translational research in hematology fields.
Research projects must be hypothesis-driven and directly connected to some aspects of human biology. Projects may encompass any form of cellular, molecular, structural, biochemical, genetic, or other appropriate experimental approach using human biological material or human subjects with the aim of reaching novel insights into human biology. Pilot and early phase clinical studies translating the laboratory discoveries "to the bedside" may be included in the proposal, however, pure clinical trial projects with laboratory correlatives will not be considered.

Sponsor Details

Sponsor Institute/Organizations: American Society of Hematology

Sponsor Type: Corporate/Non-Profit

Address: 2021 L Street NW, Suite 900, Washington, DC 20036 Contact Phone 202-776-0544 Toll Free 866-828-1231 Fax 202-776-0545

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity